Home › Follicular Lymphoma › Kentucky › Lexington
Follicular Lymphoma clinical trials in Lexington, KY
5 studies for Follicular Lymphoma are looking for participants at sites in and around Lexington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
RecruitingPhase 2/3
- University of Kentucky ( Site 1303), Lexington
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
RecruitingPhase 3
- Research Site, Lexington
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
RecruitingPhase 1
- University of Kentucky/Markey Cancer Center, Lexington
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
- University of Kentucky, Lexington
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RecruitingPhase 3
- Local Institution - 0218, Lexington
Follicular Lymphoma trials in other cities
- New York City, NY24 studies
- Milwaukee, WI19 studies
- Nashville, TN18 studies
- Houston, TX18 studies
- Boston, MA17 studies
- Baldwin Park, CA16 studies
- Seattle, WA15 studies
- Durham, NC15 studies
- Columbus, OH13 studies
- Salt Lake City, UT13 studies
- Chicago, IL12 studies
- San Antonio, TX12 studies
Other studies in Lexington
- Non-Small Cell Lung Cancer23 studies
- Lung Cancer18 studies
- Ovarian Cancer16 studies
- Prostate Cancer14 studies
- Cancer (all types)14 studies
- Breast Cancer14 studies
- Metastatic Cancer11 studies
- Colorectal Cancer11 studies
- Heart Failure11 studies
- Melanoma10 studies
- Acute Myeloid Leukemia10 studies
- Obesity10 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.